Skip to main content
Celon Pharma S.A. logo

Celon Pharma S.A. — Investor Relations & Filings

Ticker · CLN ISIN · PLCLNPH00015 LEI · 259400Q0ERJT0NC5DT24 WAR Manufacturing
Open in API
Filings indexed 709 across all filing types
Latest filing 2017-07-24 Director's Dealing
Country PL Poland
Listing WAR CLN

About Celon Pharma S.A.

https://celonpharma.com/en/

Celon Pharma S.A. is an integrated pharmaceutical company that conducts advanced research and manufactures modern drugs. The company is engaged in the development, production, distribution, and marketing of therapeutic solutions. Its primary focus is on developing treatments for cancers, neurological diseases, diabetes, and other metabolic disorders. As a marketing authorization holder, Celon Pharma manages the full product lifecycle, from scientific research and development to commercialization, aiming to improve patient health and quality of life.

Recent filings

Filing Released Lang Actions
Korekta raportu bieżącego nr 20/2017 - Powiadomienie o transakcji dotyczącej akcji Celon Pharma S.A - Content (PL)
Director's Dealing Classification · 98% confidence The document text is very short (283 characters) and states that the Management Board is correcting an omission by attaching a notification received from a Board Member (Iwona Giedronowicz) regarding a transaction involving the company's shares. A transaction by a director/executive concerning company shares directly corresponds to the definition of Director's Dealing (DIRS). Although it is an announcement correcting a previous filing, the core subject matter is the director's transaction, making DIRS the most specific fit over a general RPA or RNS, given the explicit content.
2017-07-24 Polish
Powiadomienie o transakcji dotyczących akcji Celon Pharma S.A - Content (PL)
Director's Dealing Classification · 98% confidence The document is a 'Raport bieżący' (Current Report) from CELON PHARMA S.A. The subject is 'Powiadomienie o transakcji dotyczącej akcji' (Notification of a transaction concerning shares) and the legal basis cited is 'Art. 19 ust. 3 MAR - informacja o transakcjach wykonywanych przez osoby pełniące obowiązki zarządcze' (Article 19(3) MAR - information on transactions carried out by persons discharging managerial responsibilities). This directly corresponds to insider trading notifications by directors/executives. This matches the definition for Director's Dealing (DIRS). Although the actual notification is an attachment, the primary nature of this filing is the disclosure of insider transactions, making DIRS the most specific fit over a general RPA or RNS.
2017-07-24 Polish
Otrzymanie od GLG Pharma LLC informacji o zawarciu porozumień w sprawie powstrzymania się od rozporządzania akcjami Spółki. - Content (PL)
Major Shareholding Notification Classification · 95% confidence The document is a formal notification from the Management Board (Zarząd) of GLG Pharma S.A. regarding an agreement (Porozumienia) reached by a major shareholder (GLG Pharma LLC) with institutional investors. This agreement imposes a 24-month lock-up period on 4.5 million shares (Series E). The core subject is a restriction on the disposal of shares by a significant owner, which directly relates to changes in share ownership or control over those shares. This aligns best with the definition of Major Shareholding Notification (MRQ), which covers changes in significant share ownership levels, even if the change is a restriction rather than an acquisition/disposal event itself, as it impacts the tradable float and control structure. It is not a Director's Dealing (DIRS) as it concerns a corporate shareholder, nor is it a general Share Issue/Capital Change (SHA) as it is a contractual restriction on existing shares.
2017-07-17 Polish
Rejestracja leku Salmex na rynkach w Gwatemali oraz w Salwadorze - Content (PL)
Regulatory Filings Classification · 95% confidence The document text is very short (782 characters) and announces specific business developments: the registration of a drug (Salmex/Ventiflu Discus) in Guatemala and El Salvador via a business partner. This is a specific operational update related to market expansion and product commercialization. It is not a full financial report (10-K, IR), an earnings release (ER), a management discussion (MDA), or a director's dealing (DIRS). It is a specific regulatory/business event announcement. Given the options, this type of specific operational update that doesn't fit the defined financial or governance categories (like DIV, CAP, MANG) is best categorized as a general Regulatory Filing (RNS), as it is an official announcement of a material event that doesn't match a more specific code. It is not a Report Publication Announcement (RPA) because it is announcing a business event, not the publication of a formal report.
2017-07-14 Polish
Zawarcie umów objęcia akcji serii F emitowanych w ramach kapitału docelowego. - Content (PL)
Share Issue/Capital Change Classification · 98% confidence The document text, written in Polish, discusses the completion of a private subscription ('subskrypcji prywatnej') for Series F shares ('akcji serii F'). It details the number of shares offered (1.3 million), the issue price (2.25 PLN per share), the total funds raised (2.925 million PLN), and the intention to list these shares on the NewConnect market. This content directly relates to the issuance of new shares and changes in the company's capital structure. This aligns perfectly with the definition for 'Share Issue/Capital Change' (SHA). The document is not a mere announcement of a report (RPA/RNS) but contains the substantive details of the capital event itself.
2017-07-14 Polish
Zarekomendowanie przez NCBiR wniosku o dofinansowanie trzech projektów Spółki - Content (PL)
Regulatory Filings Classification · 99% confidence The document is a short announcement (1430 characters) from the Management Board of Celon Pharma S.A. (Zarząd Celon Pharma S.A.) informing the public that three of the company's applications for project co-financing under the InnoNeuroPharm sector program, managed by the National Centre for Research and Development (NCBiR), have been recommended for funding. It details the project names, total costs, and recommended funding amounts. This is a specific announcement regarding financing/funding recommendations, which aligns best with the 'Capital/Financing Update' category (CAP). It is not a full report (10-K, IR), an earnings release (ER), or a general regulatory filing (RNS), as it concerns a specific capital/funding event.
2017-07-06 Polish

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.